University of Crete (UOC)
Study of the impact of dyslipidemias on rheumatoid arthritis and immunometabolism using mouse models
Abstract
dc:descriptionCardiovascular Diseases (CVD) remain the leading cause of mortality worldwide and are inextricably linked to conditions of chronic, low-grade inflammation and dyslipidemia. In patients suffering from autoimmune inflammatory diseases, such as rheumatoid arthritis (RA), the risk of developing CVD is significantly elevated, indicating the existence of common pathophysiological mechanisms between chronic inflammation and atherosclerosis. Serum cholesterol, triglycerides, and triglyceride-rich lipoproteins (TRLs) play an active role in the pathogenesis of such diseases by activating pro-inflammatory pathways. A crucial regulator of cholesterol metabolism is apolipoprotein E (ApoE), while for TRLs it is apolipoprotein C-III (ApoC-III). Furthermore, the qualitative dysfunction of high-density lipoproteins (HDL), independent of HDL cholesterol concentration, has been recognized as a critical factor in immune dysregulation. Under conditions of chronic inflammation, HDL loses its antioxidant and anti-inflammatory properties, partly through a decrease in paraoxonase-1 (PON-1) activity and alterations in the content of apolipoprotein A-I (ApoA-I).In the first part of the present thesis, it was investigated whether combined dyslipidemia induced by the overexpression of ApoC-III affects the pathogenesis of RA, along with the effect of hypolipidemic treatment using fenofibrate. High serum levels of ApoC-III are associated with the inhibition of lipoprotein lipase (LPL) and delayed hepatic clearance of TRLs, resulting in increased serum triglycerides. Additionally, recent data suggest a direct role for ApoC-III in the activation of inflammatory pathways in monocytes and macrophages, cells that are involved in both atherosclerosis and RA. To achieve the objectives of the study, the experimental model of antigen-induced arthritis (AIA) in transgenic APOC3 mice (known as ApoC-III Tg) was utilized. This mouse line overexpresses human ApoC-III protein and exhibits a combined dyslipidemia phenotype (severe hypertriglyceridemia, high total cholesterol, reduced HDL levels). In our experiments, ApoC-III Tg mice developed significantly more severe joint swelling following AIA induction compared to control mice, which was observed macroscopically by measuring knee swelling, as well as by histological analysis of the joints that confirmed the clinical picture. Analyzing the serum of the experimental animals after the completion of the protocol, it was confirmed that the arthritic ApoC-III Tg mice maintained their dyslipidemic profile (high levels of triglycerides and total cholesterol, with concurrently reduced HDL cholesterol levels). Further analysis of the lipoprotein fractions showed reduced levels of ApoA-I, the main protein of HDL. Conversely, human ApoC-III was detected in all fractions, with a significant concentration in VLDL and LDL, similarly to healthy –without AIA– ApoC-III Tg mice, indicating that the inflammatory state is accompanied by significant quantitative and qualitative alterations in the lipoprotein profile. In order to evaluate the functional consequences of these alterations, the antioxidant capacity of the isolated HDL was examined. HDL from arthritic ApoC-III Tg mice exhibited significantly reduced enzymatic activity of PON-1 and a reduced capacity to inhibit LDL oxidation, compared to the control group.These results suggest an overall dysfunction of the HDL particles under hypertriglyceridemic conditions. Furthermore, the direct impact of the dysfunctional HDL on macrophages was investigated through ex vivo incubations. Mitochondrial respiration analyses using the Seahorse system (Agilent) revealed a decrease in the oxygen consumption rate (OCR), maximal respiratory capacity, and coupling efficiency in primary macrophages exposed to HDL from transgenic mice. At the gene expression level in RAW 264.7 macrophages, the same HDL led to a significant increase in the expression of pro-inflammatory markers, such as iNOS, IL-1β, and TNF-α, confirming its role in promoting a pro-inflammatory (M1) phenotype. Subsequently, aiming to treat hypertriglyceridemia, fenofibrate (100 mg/kg/day, i.p. for 7 days) was systematically administered to the ApoC-III Tg mice following the onset of arthritis. The treatment led to the regression of knee swelling and the protection of the joint architecture, as shown histologically. The improvement in the clinical picture was accompanied by a drastic reduction in serum triglyceride and total cholesterol levels. Concurrently, fenofibrate restored HDL functionality by increasing PON-1 activity, improving its antioxidant capacity, and partially reversing structural changes by increasing ApoA-I levels. Although the effect of the improved HDL on the pro-inflammatory gene expression levels of macrophages was marginal, the overall improvement of dyslipidemia demonstrated the critical role of lipids in disease exacerbation. In conclusion, this research confirms that hypertriglyceridemia driven from ApoC-III overexpression promotes inflammation in autoimmune diseases. Dyslipidemia leads to the loss of HDL's protective role, transforming it into a particle that promotes metabolic dysregulation and the inflammatory action of macrophages, thereby exacerbating the clinical picture of RA. Therapeutic targeting of triglycerides through agents such as fenofibrate can reverse these pathological changes, highlighting the importance of an approach that targets dyslipidemia to limit inflammation. In the second part of the present thesis, the impact of a hypercholesterolemic background on the development and severity of RA was investigated, along with the evaluation of the effects of hypolipidemic treatment with simvastatin. Hypercholesterolemia, and dyslipidemia in general, are conditions closely linked to inflammation. Cholesterol accumulation in innate immune cells, including macrophages, promotes their activation and a shift towards pro-inflammatory phenotypes. To achieve the thesis’ objectives, the genetically modified ApoE knockout (ApoE KO) mouse model was used, and arthritis was induced via the AIA protocol. Our analyses showed that ApoE KO mice exhibited a more severe course of arthritis with greater knee swelling from the early stages of the disease, compared to control B6 mice, which was confirmed by the histological analysis of the joints. At the biochemical level, the mice maintained high levels of total cholesterol and significantly reduced levels of HDL cholesterol, with a concurrent decrease in PON-1 activity. Furthermore, the analysis of ApoA-I distribution in the lipoprotein fractions revealed a localization discrepancy. Its presence in low-density fractions indicates a significant reorganization and qualitative alteration of the HDL particles.Phenotypic analysis of splenic macrophages from ApoE KO mice revealed alterations in surface markers compared to the control group. At the peak of arthritis, enhanced expression of the costimulatory molecule CD86 and the antigen-presenting molecule MHC-II was observed, while at the final stage, ApoE KO macrophages presented increased expression of CD163 and CD86, which are also associated with immune activation. These data support that hypercholesterolemia leads to macrophage reprogramming by enhancing their pro-inflammatory function. The administration of simvastatin (20 mg/kg/day, i.p. for 7 days) to the ApoE KO mice improved the lipid profile, significantly restored HDL’s PON-1 functionality, and reduced the severity of arthritis. Additionally, the phenotypic profile of macrophages from the same mice showed a reduction in characteristics associated with increased immune activation. These findings highlight that hypolipidemic treatment not only affects the metabolic aspect of the disease but also directly impacts immunological processes. In conclusion, the current research demonstrates that hypercholesterolemia influences the inflammatory response in RA through the remodeling of macrophage function and the qualitative composition of lipoproteins. Understanding the interaction between lipid metabolism and innate immunity may open new therapeutic avenues that simultaneously target inflammation and metabolic dysfunction by improving dyslipidemia, with the aim of better prognosis not only for arthritis but also for its closely related cardiovascular complications.Overall, this thesis investigates the critical crosstalk between lipid metabolism and inflammation in the pathogenesis of RA utilizing two distinct dyslipidemic mouse models, the ApoC-III Tg and the ApoE KO. Our research demonstrates that both hypertriglyceridemia and hypercholesterolemia significantly exacerbate joint inflammation and structural damage. Despite the model differences, a shared underlying mechanism was identified suggesting that, under dyslipidemic conditions, HDL undergoes structural and functional impairment, characterized by diminished PON-1 antioxidant activity and altered apolipoprotein composition. This qualitative loss of HDL’s protective properties drives the reprogramming of macrophages toward a pro-inflammatory phenotype. Crucially, targeted hypolipidemic interventions not only reversed the lipid imbalances but also restored HDL functionality, reduced macrophage activation, and successfully ameliorated the clinical and histological severity of RA. This work highlights that therapeutic strategies targeting lipid profiles offer dual metabolic and immunological benefits, providing a promising approach to mitigating both arthritis severity and its associated cardiovascular risks in clinical practice.
Degree
thesis:*- Grantor dc:publisher
- University of Crete (UOC)
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Axiotis, Isidoros
- Αξιώτης, Ισίδωρος
Subjects
dc:subject × 25- Τριγλυκερίδια
- Χοληστερόλη
- HDL
- Ρευματοειδής αρθρίτιδα (ΡΑ)
- Φιμπράτες
- Στατίνες
- Μακροφάγα
- Απολιποπρωτεΐνη C3
- Απολιποπρωτεΐνη Ε
- Triglycerides
- Cholesterol
- Rheumatoid arthritis
- Fibrates
- Statins
- Macrophages
- Apolipoprotein CIII
- Apolipoprotein E
- Βασική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Βασική ιατρική, γενικά
- Ιατρική βιοχημεία
- Basic Medicine
- Medical and Health Sciences
- Basic medicine, general
- Medical Biochemistry
Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/61738